Sentence examples for assay discrepancies from inspiring English sources

Data were evaluated for intra- and inter-laboratory variation, accuracy and possible rFVIIIFc-specific assay discrepancies.

Further studies using clinical samples may be needed to confirm these assay discrepancies and to determine whether the increased chromogenic activity observed for rFVIIIFc has a noticeable clinical impact in the background of the already high inter-laboratory variability.

Furthermore, it is important to note that both of the previous studies used a different ELISA assay, and discrepancies in protein concentration calculations could arise when using different antibodies (Kristinsson et al, 1998).

Since the data and blood sample collection in the two studies are separated by 15 years, we should acknowledge that differences in patient care, ICU admission policies, the nature of the patient mix, the use of retrospective analysis of data, methods of blood collection and shipping and the technology for LBP assays could explain discrepancies in the reported LBP values.

We verified the expression levels of hsa-miR-299-5p hsa-miR-299-5p hsa-miR-299-5p hsa-miR-299-5penitors and CD34 HPC samicroRNAing TanMan real-tindependentividual asety and nofsignificant discrepancies were observed whumanomprogenitorsthe results obtanded with TaqMan miCD34NA Assays HPCan Panel Early Accesamples(Foster City, CA, using(SupplemenTaqManigure S2).

All of our LND variants who had enzyme activity measured in live cells displayed measurable residual activity, and discrepancies between assays from live cells versus lysates were evident for many cases that had both assays (Table 1).

Remarkably, these results were mirrored exactly by both the one- and two-step r-Δgp160-based TRF assays, with no discrepancy in any of the samples whatsoever.

(In the MER-ATP study's field tests, when aliquots of the same collected samples were examined with both the ATP assay and NSA, no such discrepancies were actually observed).

The inconsistency in performance of the A1C test among studies may have been due to the discrepancies in ethnicity, assay methods for A1C, the gold standard for diagnosis of diabetes, study methodology differences (population-based versus clinical based), and the prevalence of other risk factors such as obesity.

Significant discrepancies between the two assays were observed, the MTT assay consistently underestimating the growth inhibitory effects of the IFNs.

We do not know the reason for the discrepancy but different assay conditions could contribute.